Oxford BioMedica plc
Company Information

Medawar Centre
Oxford, Oxfordshire, OX4 4GA England

Top 3 Competitors

Unlock access to all reports with a Hoover's Professional Subscription
Call (866) 473-3932 today to get
started with a FREE TRIAL!

  • Up-to-the moment intelligence helps you set strategy, prepare for sales calls, and close business.
  • Easy-to-read reports on over 85 million companies and 900 industries build your understanding of the companies you work with.
  • High-quality, reasonably-priced reports save you hours of costly research.

Unlock a Hoover's Basic Subscription.
To talk to a Business Information Consultant please call (866) 473-3932


Oxford BioMedica plc Company Profile

Oxford BioMedica has no reservations about launching attacks on disease. The biotechnology company uses gene therapy and immunotherapy to develop treatments for cancer, as well as neurodegenerative and ocular diseases. Its four ocular gene therapies are partnered with Sanofi; the company works with Pfizer on another targeted antibody therapy. The company has three lead products: TroVax, ProSavin, and RetinoStat (being developed with Sanofi). TroVax is in late-stage clinical trials for the treatment of prostate cancer. ProSavin is being tested to treat Parkinson's disease using the company's LentiVector platform. RetinoStat is in clinical trials to treat wet age-related macular degeneration.